How to derive and expand primary tumor cell cultures [WEBINAR]

This webinar covers Miltenyi Biotec’s latest solutions for improved culture of primary and xenotransplanted tumor cells. Get insights into dissociation of fresh tumor samples into viable single-cell suspensions, untouched isolation of fully viable, heterogeneous tumor cells, and in vitro derivation and expansion of primary and xenotransplanted tumor cell cultures while preserving parental tumor heterogeneity, tumor-initiating capacity, and genetic stability.

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. Our 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has 2,500 employees in 28 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.